Plasma Pentraxin-3 levels are increased in NASH patients, especially those with more severe disease (stages 3-4) compared to less severe disease (stages 0–2) and non-NASH (NAFLD patients) [39]. This evidence concerns the gene PTX3 and metabolic dysfunction-associated steatohepatitis.